相关实验视频
Updated: Mar 16, 2026

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.4K
形性关节炎患者的动脉样硬化TNFα抑制剂的影响:系统审查协议
Yasmine Makhlouf1, Hiba Boussaa1, Hiba Bettaieb2
1Department of rheumatology, Mongi Slim Hospital, Sidi Daoued, La marsa, 2046, Tunisia. University Tunis El Manar.
La Tunisie medicale
|March 15, 2026
概括
本综述评估了TNF-α抑制剂是否会影响牛皮关节炎 (PsA) 患者的动脉样硬化进展. 分析了高质量的研究,以了解这些心血管影响.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 牛皮关节炎 (PsA) 是一种慢性炎症性疾病,与心血管疾病风险增加有关,特别是动脉样硬化,由于全身炎症.
- 瘤坏死因子-α (TNF-α) 抑制剂用于管理PsA炎症,对血管健康有潜在的益处,尽管它们对PsA动脉样硬化进展的直接影响尚未完全理解.
研究的目的:
- 系统地审查和评估TNF-α抑制剂对被诊断患有牛皮关节炎的成年患者动脉样硬化进展的影响.
主要方法:
- 一个遵循PRISMA指南的系统审查,包括原始的观察研究和RCT.
- 在PubMed,Scopus,Embase和Cochrane图书馆进行的搜索,专注于测量动脉样硬化或内皮功能障碍的研究.
- 使用纽卡斯尔-太华尺度和ROB 2工具评估的高质量研究,用于数据分析的叙事综合.
主要成果:
- 审查正在进行中,将综合精选的高质量研究的发现.
- 数据提取和质量评估由两个独立审查员进行.
- 综合将重点关注TNF-α抑制剂对PsA患者动脉样硬化标志物的影响.
结论:
- 这些发现将澄清TNF-α抑制剂在治疗牛皮关节炎中的动脉样硬化中的作用.
- 本综述旨在为临床实践提供基于证据的见解,以了解在接受TNF-α抑制剂治疗的PsA患者心血管风险.
相关概念视频
Atherosclerosis III: Management
562
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
562
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
697
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
697
T Cell Types and Functions
3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
Atherosclerosis IV: Nursing Management
553
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
553
Inflammatory Bowel Disease IV: Pharmacological Management
895
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
895
